Caribou Biosciences Presents Case Report On Long-Term Follow Up Of First Patient Dosed In Phase 1 ANTLER Trial At The Lymphoma, Leukemia, & Myeloma Congress 2022 October 18-22
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of a case report for long-term follow up on the first patient